Suffering from prostate cancer or benign prostatic hyperplasia (BPH) is not the end of a relationship. Technology and ...
OXFORD, UK / ACCESS Newswire / June 15, 2026 /Fine Treatment has highlighted increasing interest in non-invasive therapeutic ...
AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption ...
The prevalence of benign prostatic hyperplasia is increasing globally, according to a study published online Oct. 20 in The Lancet Healthy Longevity. Atalel Fentahun Awedew, M.D., from Addis Ababa ...
AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will ...
Patients with gout, especially those younger than 60 years, have an increased risk for benign prostatic hyperplasia (BPH), according to a study published online Dec. 26 in Diagnostics. Woo Jin Bang, ...
Fine Treatment participates in many meetings and conferences in the UK, including most recently the Oxford Innovation ...
JW Pharmaceutical and JW Shinyak announced on the 10th that they held the "J STAR Symposium" at the Grand Walkerhill Seoul ...
Frequent urination, urgency and waking up at night to urinate are often blamed on an enlarged prostate. However, doctors say ...
(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...